Objectives Low vitamin D levels are associated with the severity and mortality of COVID-19 infection. Nevertheless, the relationship between the 25-hydroxyvitamin D [25(OH)D] levels and the antibody response following COVID-19 vaccination is not fully elucidated. Herein, we explored the relationship between SARS-CoV-2 IgG (sCOVG) and 25(OH)D. Methods In this prospective observational case-control study, we used an automated chemiluminescent immunoassay method to measure sCOVG and 25(OH)D levels in 96 patients 28 days following the second dose of inactivated vaccine. We considered the positivity for sCOVG at three different index values: 1, 2.42, and 7. We classified 25(OH)D levels between 0 and 20 ng/mL as vitamin D deficiency, 21–29 ng/mL as insufficiency and 30 ng/mL as sufficiency. Results Median sCOVG index was 6.02 (interquartile ranges 3.41–11.63) and median 25(OH)D level was 11.5 ng/mL (interquartile ranges 10–17). We could not find a significant correlation between 25(OH)D and sCOVG levels (Spearman’s rho, r=0.175, p=0.12). When considering the variables categorically, we did also not conclude significant relationships between adequate or inadequate antibody responses in patients with deficient, insufficient, and sufficient 25(OH)D by three sCOVG cut-off index values (1, 2.42, and 7) (Chi-square test, p=0.8, 0.29, and 0.08, respectively). Conclusions The relevant literature is limited on the association between the antibody response to COVID-19 vaccines and vitamin D levels. Although the previous research suggested conflicting findings of the response to mRNA vaccines, we could not conclude a significant relationship between sCOVG and 25(OH)D levels 28 days after two doses of inactivated COVID-19 vaccine.
Background. Effective triage is critical during the coronavirus disease 2019 pandemic. An appropriate triage plan is crucial to direct suspected COVID-19 cases to a designated area, in order to separate such patients from other patients and staff.Objectives. To report the diagnostic value of the "Possible Coronavirus Disease 2019 (COVID-19) Case Questioning Guide for Outpatients", a nationwide standard triage chart, and of the individual questions within the triage chart for detecting COVID-19 in patients admitted to our hospital. Materials and methods.A total of 39,681 outpatients admitted to our hospital between April 1 and April 30, 2021, underwent triage questioning. The triage chart consisted of 3 symptom questions and 4 contact and travel questions. Patients who responded "yes" to at least 1 question were referred to the pandemic area; others were considered low-risk and did not undergo routine COVID-19 polymerase chain reaction (PCR) test.Results. Briefly, 3529 outpatients were referred to the pandemic area; among them, 1055 were PCR-positive. Among 36,152 low-risk patients, 94 were PCR-positive. The sensitivity of the triage chart was 91.82%, specificity was 93.58%, positive likelihood ratio was 14.30, and negative likelihood ratio was 0.09. Triage questions were in moderate agreement with PCR results (Cohen's Kappa: 0.429, p < 0.0001). The diagnostic value of the triage chart was mainly attributed to the questions regarding possible COVID-19 infection symptoms rather than contact history. However, the questions included in the triage chart had none to slight agreement with the PCR test results in the pandemic outpatients. Conclusions.The triage chart has high sensitivity and specificity for discriminating possible COVID-19 cases in all outpatients, but has unsatisfactory diagnostic value for predicting PCR positivity in pandemic outpatients. Therefore, the current triage chart should be used accordingly, i.e., to define possible COVID-19 cases rather than PCR-positive cases. Further studies regarding COVID-19 triage for possible and PCR-positive cases should also focus on the individual diagnostic value of less prevalent symptoms.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.